Trials / NCT05077956
Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
Withdrawn Observational Natural history / observational
Why it stopped: No participants were enrolled before closing the study
- Sponsor
- Providence Health & Services
- Treatment
- Cerebrospinal and Blood Serum Semaphorin 4A Levels
- Gene
- Not stated
- Conditions
- Relapsing Multiple Sclerosis, Multiple Sclerosis
- Ages
- 18 Years to 55 Years
- Enrollment
- Not stated participants
- Started
- 2021-10-19
- Main results expected
- 2023-10-25
- Results posted
- Not yet
- Record last updated
- 2023-08-07
What the study is testing
Measure serum and cerebrospinal fluid Sema4A levels in female subjects with newly diagnosed and untreated relapsing multiple sclerosis, clinically stable relapsing multiple sclerosis receiving disease modifying therapy, relapsing multiple sclerosis receiving disease modifying therapy with breakthrough disease, or non-multiple sclerosis controls (patients without inflammatory central nervous system disease).
Where it runs
United States (1)
- Providence St. Vincent Medical Center, Portland, Oregon